Stefano Cascinu

Professore Ordinariop

Università Vita Salute San Raffaele

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Cancer Biology Cancer Biology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Stefano Cascinu is a Professore Ordinario at Università Vita Salute San Raffaele in Italy. His research focuses on oncology, particularly in the treatment and outcomes of pancreatic, gastric, and colorectal cancers. Recent studies include investigations on combination therapies, immunotherapy responses, and nutritional support protocols for cancer patients. He is actively engaged in studies assessing biomarkers and clinical outcomes in advanced cancer therapies.

Articles (10)

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

MONIA MACCAFERRI

University of Modena and Reggio Emilia

ITALY

View details

Fabio Gelsomino

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Stefano Cascinu

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial

Tumor Response and Symptom Palliation from RAINBOW , a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer

Imaging and clinical correlates with regorafenib in metastatic colorectal cancer

Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial

Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response

Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis

Oral anticancer therapy project: Clinical utility of a specific home care nursing programme on behalf of Italian Association of Medical Oncology (AIOM)

Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes

Collaborators (2)

MONIA MACCAFERRI

Fabio Gelsomino

Make your next move.